MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, ACRS had -$146K decrease in cash & cash equivalents over the period. -$10,955K in free cash flow.

Cash Flow Overview

Change in Cash
-$146K
Free Cash flow
-$10,955K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
-14,614 -30,514
Depreciation and amortization
110 242
Stock-based compensation expense
2,860 6,598
Revaluation of contingent consideration
100 1,800
Accounts receivable
--124
Accounts receivable, prepaid expenses and other assets
-6,810 -
Accounts payable
377 4,107
Prepaid expenses and other assets
--7,031
Accrued expenses and other liabilities
1,295 -10,643
Deferred income
-715 -1,795
Net cash used in operating activities
-10,932 -23,050
Purchases of property and equipment, net
23 64
Purchases of marketable securities
5,198 29,926
Proceeds from sales and maturities of marketable securities
19,051 54,989
Payment of deferred transaction consideration for in-licensed assets
0 833
Net cash provided by investing activities
13,830 24,166
Payment of deferred transaction consideration for in-licensed assets
3,044 -
Payments of employee withholding taxes related to restricted stock unit award vesting
0 284
Net cash used in financing activities
-3,044 -284
Net increase in cash and cash equivalents
-146 832
Cash and cash equivalents at beginning of period
24,570 -
Cash and cash equivalents at end of period
25,256 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Aclaris Therapeutics, Inc. (ACRS)

Aclaris Therapeutics, Inc. (ACRS)